Atom Therapeutics Enrolls First Patient in Multicenter Global Phase 2 Trial of ABP-745 for Acute Gout Flares
Atom Therapeutics, a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, announced today it has enrolled the first patient in a multi-country Phase 2 trial of ABP-745, a novel anti-inflammatory drug, for treatment of painful acute gout flares.
